|Traded as||NASDAQ: TTNP|
Number of employees
|13 (June 2015)|
Titan Pharmaceuticals, Inc. is a California biopharmaceutical company developing proprietary therapeutics primarily for the treatment of central nervous system ("CNS") disorders.
Titan's principal asset is Probuphine, a slow-release implant formulation of buprenorphine hydrochloride ("buprenorphine") for the treatment of opioid addiction or chronic pain. FDA Approval was granted on 26 May 2016.
- Solof, Barry (2013). The therapist's guide to addiction medicine a handbook for addiction counselors and therapists. New York: Central Recovery Press, LLC. p. 98. ISBN 9781937612443. Retrieved 21 September 2015.
- "Press Announcements - FDA approves first buprenorphine implant for treatment of opioid dependence". www.fda.gov. Retrieved 26 May 2016.